The acne treatment is produced under the beauty company’s La Roche-Posay skin care brand and contains benzoyl ... 2024 and will be available to consumers soon.” It comes after US lab Valisure found ...
Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent.
2d
Indy100 on MSNPopular La Roche-Posay product recalled over 'cancer-causing chemical' fears - here's what we knowA voluntary recall issue has been served for a popular La Roche-Posay product in the US after it was found among 66 leading ...
The U.S. Food and Drug Administration issued a recall notice Tuesday for several lots of six products, including Walgreens Acne Control Cleanser, Proactiv Skin Smoothing Exfoliator, SLMD Benzoyl ...
Some acne treatments from brands including Walgreens, Proactiv and La-Roche Posay have been voluntarily recalled for ...
Parent company La Roche-Posay has pulled the Effaclar Duo Acne Spot Treatment from L'Oreal's lineup, due to a cancer-causing ...
L'Oréal has urgently recalled one of its popular La Roche Posay face creams over fears it ... It also comes just a year after an independent lab detected high levels of benzene in several ...
La Roche-Posay Effaclar Duo Dual Action Acne Treatment (lot number MYX46W; expiration date, April 2025) Walgreens Acne Control Cleanser (lot number 23 09328; expiration date, September 2025) ...
LOWER POTTSGROVE — Dermatology Partners has completed and opened a new dermatopathology laboratory in Lower Pottsgrove Township, Montgomery County — just outside of Pottstown. The new lab, 2023 E.
Here is what we know. L’Oreal has issued a voluntary recall of their popular Effaclar Duo. This product is under the La Roche-Posay brand A new, improved formula will replace the previous version and ...
alliance with Adaptimmune that could be worth up to $3 billion, as well as $2 billion alliance with Adaptive Biotech focusing on TCR therapies for solid tumours. Roche may be a relative ...
Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results